Cullinan Oncology to Participate in William Blair Biotech Focus Conference
July 05 2022 - 4:01PM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a
biopharmaceutical company focused on developing a diversified
pipeline of targeted therapies for patients with cancer, today
announced that its Chief Scientific Officer, Patrick Baeuerle,
Ph.D., will deliver a keynote presentation at the William Blair
Biotech Focus Conference, being held July 12-13, 2022 in New York.
Dr. Baeuerle’s presentation, titled “Multispecific
Protein Therapies: Where We’ve Been and Where We’re Going?” is
scheduled for Tuesday, July 12 at 1:00 p.m. EDT.
In addition to Dr. Baeuerle’s keynote presentation,
Cullinan Oncology’s management team will be participating in
one-on-one meetings with attendees. Investors attending the
Conference who are interested in meeting with management are
encouraged to contact their William Blair representative.
About Cullinan Oncology Cullinan
Oncology, Inc. (NASDAQ: CGEM) is a biopharmaceutical company
dedicated to creating new standards of care for patients with
cancer. We innovate without borders to find the most promising
clinic-ready cancer therapies, whether from our own discovery
efforts or through exceptional engagement with our academic and
industry partners. Anchored in a deep understanding of
immuno-oncology and translational cancer medicine, we leverage our
scientific excellence in small molecules and biologics to create
differentiated ideas, identify unique targets, and select the
optimal modality to develop transformative therapeutics across
cancer indications. Powered by our novel research model, we push
conventional boundaries from candidate selection to cancer
therapeutic, applying rigorous early experimentation to fast-track
only the most promising assets to the clinic and ultimately
commercialization. As a result, our diversified pipeline is
strategically built with assets that activate the immune system or
inhibit key oncogenic drivers across a wide range of modalities,
each with the potential to be the best or first in their class.
Our people possess deep scientific expertise, seek
innovation openly, and exercise creativity and urgency to deliver
on our promise to bring new therapeutic solutions to patients with
cancer. Learn more about our Company at www.cullinanoncology.com,
and follow us on LinkedIn and Twitter.
Contacts: Investor Relations Chad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1
215.801.7644rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024